Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: adnectin-based therapeutics - Bristol-Myers Squibb

Drug Profile

Research programme: adnectin-based therapeutics - Bristol-Myers Squibb

Alternative Names: Bispecific Adnectin™ inhibitor; Bispecific EGFR-IGFR Adnectins™; EGFR/IGFR tandem adnectin; EI-tandem; FGF21-PKE Adnectin™; IL-23 Adnectin inhibitor™; IL-23 Adnectin™

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adnexus Therapeutics
  • Developer Bristol-Myers Squibb
  • Class Proteins
  • Mechanism of Action Epidermal growth factor receptor antagonists; Fibroblast growth factor 21 agonists; Insulin-like growth factor-I receptor antagonists; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Immunological disorders
  • Discontinued Metabolic disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Immunological-disorders in USA (Parenteral)
  • 08 Sep 2015 Preclinical development is underway in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top